Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Immunological Bridging Study Assessing the Non-inferiority of a New Formulation of ETVAX®. A Prospective Double-blind, Randomized Study in Healthy Volunteers.

NCT05178134 is registered in ClinicalTrials.gov with Scandinavian Biopharma AB as lead sponsor.

NCT NCT05178134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05178134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Immunological Bridging Study Assessing the Non-inferiority of a New Formulation of ETVAX®. A Prospective Double-blind, Randomized Study in Healthy Volunteers.
Lead sponsor
Scandinavian Biopharma AB
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2021
Completion date
October 20, 2022
Enrollment
280 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healty volunteers, preventable disease, vaccine